CELLDEX THERAPEUTICS INC NEW's ticker is and the CUSIP is 15117B902. A total of 3 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $462,336 | +21.7% | 16,800 | +50.0% | 0.00% | +100.0% |
| Q2 2023 | $380,016 | -73.4% | 11,200 | -71.8% | 0.00% | -80.0% |
| Q1 2023 | $1,428,406 | -24.1% | 39,700 | -5.9% | 0.01% | +25.0% |
| Q4 2022 | $1,880,854 | +57.1% | 42,200 | -0.9% | 0.00% | +100.0% |
| Q3 2022 | $1,197,000 | -65.2% | 42,600 | -66.6% | 0.00% | -60.0% |
| Q2 2022 | $3,435,000 | +164.0% | 127,400 | +233.5% | 0.01% | +400.0% |
| Q1 2022 | $1,301,000 | +14.1% | 38,200 | +29.5% | 0.00% | 0.0% |
| Q4 2021 | $1,140,000 | -32.5% | 29,500 | -5.8% | 0.00% | -50.0% |
| Q3 2021 | $1,690,000 | +115.0% | 31,300 | +33.2% | 0.00% | +100.0% |
| Q2 2021 | $786,000 | +35.3% | 23,500 | -16.7% | 0.00% | 0.0% |
| Q1 2021 | $581,000 | +101.0% | 28,200 | +70.9% | 0.00% | – |
| Q4 2020 | $289,000 | -72.0% | 16,500 | -76.3% | 0.00% | -100.0% |
| Q3 2020 | $1,031,000 | -19.3% | 69,500 | -29.2% | 0.00% | -50.0% |
| Q2 2020 | $1,277,000 | +3890.6% | 98,200 | +403.6% | 0.01% | – |
| Q1 2020 | $32,000 | +357.1% | 19,500 | +550.0% | 0.00% | – |
| Q4 2019 | $7,000 | -75.9% | 3,000 | -78.3% | 0.00% | – |
| Q3 2019 | $29,000 | +480.0% | 13,800 | +590.0% | 0.00% | – |
| Q2 2019 | $5,000 | -96.9% | 2,000 | -93.8% | 0.00% | -100.0% |
| Q1 2019 | $159,000 | – | 32,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PURA VIDA INVESTMENTS, LLC | 594,800 | $16,036,000 | 0.93% |
| SIMPLEX TRADING, LLC | 369,400 | $9,959,000 | 0.01% |
| JANE STREET GROUP, LLC | 479,400 | $12,925,000 | 0.01% |
| GROUP ONE TRADING, L.P. | 127,400 | $3,435,000 | 0.01% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |